Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
September 27, 2021 08:00 ET | Phathom Pharmaceuticals
Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACIDĀ®) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK,...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
September 20, 2021 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.Ā (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
September 08, 2021 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021 07:45 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
August 10, 2021 08:00 ET | Phathom Pharmaceuticals
Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
August 05, 2021 07:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
August 02, 2021 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 25, 2021 16:01 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 11, 2021 08:00 ET | Phathom Pharmaceuticals
Positive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021U.S. Food and Drug Administration (FDA) grants...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
May 06, 2021 17:48 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...